Could an asthma drug help fight lung cancer? early trial investigates

NCT ID NCT07675876

Not yet recruiting Disease control Sponsor: Carcinex Inc Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 participants will receive the drug via a dry powder inhaler and be monitored for side effects, tumor changes, and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cromolyn sodium (inhaled)
What this could lead to: If successful, this could point toward a new way to treat lung cancer by calming inflammation in the tumor environment.
What could go wrong: This is a very early, small pilot study with only 10 people. It is designed mainly to check safety, not to prove the drug works against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER LUNG ADENOCARCINOMA

Contacts and locations

Locations

In home ttreatment

Denver, Colorado, 80220-4425, United States
Treated at home

Denver, Colorado, 80220-4425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.